Phase II data support potential benefit of bevacizumab in HIV-associated Kaposi's sarcoma Feb. 26, 2010
HSP90 inhibitor STA-9090 targets oncogenic functions of Wilms tumor protein in AML cells Feb. 25, 2010
DIVA 01 trial data indicate good penetration of raltegravir in genital tract of HIV-infected women Feb. 25, 2010
New fusion inhibitor shows potent antiviral activity in wild-type and RTI-resistant HIV strains Feb. 25, 2010
HCV RNA synthesis inhibitor ATI-0810 exhibits favorable safety and pharmacokinetics in vivo Feb. 25, 2010
Final 96-week phase II data on elvucitabine vs. lamivudine in ART-naive HIV-1 patients disclosed Feb. 22, 2010
RSS